ArticleAmerican journal of translational research2026
Decursin ameliorates diabetic kidney disease by attenuating renal epithelial-mesenchymal transition via inhibition of the PI3K/Akt pathway.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to elucidate the therapeutic mechanisms of Decursin (DE) against diabetic kidney disease (DKD), focusing on its effects on renal epithelial-mesenchymal transition (EMT) and the underlying signaling pathways.
methodsA streptozotocin (STZ)-induced DKD model was established in rats and treated with DE for 12 weeks. Metabolic and renal function indices were assessed using blood and urine samples, while kidney tissues were subjected to histopathological examination. Network pharmacology and disease database analyses were employed to predict the core target genes of DE in DKD. The predicted targets and EMT-related processes were further validated using human renal tubular epithelial cells (HK2) under high glucose (HG) or transforming growth factor-beta 1 (TGF-β1) stimulation. The expression of core target proteins and EMT markers was evaluated by Western blotting in both in vivo and in vitro settings.
resultsDE treatment significantly ameliorated biochemical parameters and renal EMT in DKD rats. Network analysis identified 16 potential target genes, with MMP-9, ESR1, PTGS2, AR, and CTNNB1 ranked as the top five core genes. Molecular docking and protein-protein interaction analysis further prioritized MMP-9, PI3K, and Akt as the most promising hub targets of DE. Consistently, Western blot analysis confirmed that DE markedly downregulated the expression of PI3K, phosphorylated Akt (p-Akt), and EMT-related proteins (including MMP-9, N-cadherin, and α-SMA) both in DKD rat kidneys and in HG- or TGF-β1-stimulated HK2 cells. Furthermore, the PI3K inhibitor LY294002 produced similar anti-EMT effects, thereby confirming the involvement of the PI3K/Akt pathway in the action of DE.
conclusionIntegrating experimental and network pharmacology approaches, this study demonstrates that DE alleviates renal EMT in DKD by inhibiting the PI3K/Akt signaling pathway, providing preliminary evidence for future studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.